Reforming PBM Practices to Alleviate Drug Costs for Patients

November 18, 2025 - 19:28

Lowering patients' drug costs requires comprehensive reforms in the pharmacy benefit manager (PBM) market. Recent trends indicate that PBMs are increasingly utilizing group purchasing organizations (GPOs), a practice that has raised concerns regarding the overall impact on drug pricing for consumers. As intermediaries between insurers, pharmacies, and drug manufacturers, PBMs have significant influence over the pricing and accessibility of medications.

The growing reliance on GPOs can lead to inflated costs for patients, as these organizations often negotiate bulk purchasing agreements that may not always translate to lower prices at the pharmacy counter. Critics argue that this model prioritizes profit over patient care, resulting in higher out-of-pocket expenses for essential medications.

To address these issues, stakeholders are calling for reforms that enhance transparency in PBM operations and ensure that savings from negotiated prices are passed down to patients. Implementing such changes could lead to more equitable access to medications and ultimately reduce the financial burden on individuals relying on prescription drugs.